A phase I/IIa study combining curcumin (Curcumin C3 Complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer

niversity of Leicester (UK)0 个研究点目标入组 28 人开始时间: 2011年10月28日最近更新: 2019年10月7日

适应症

试验速览

•1. Histological or cytological diagnosis of metastatic colorectal cancer
•2. Measurable disease by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1)
•3. Adequate haematological, hepatic and renal function
•4. Age more than or equal to 18 years
•5. Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1
•6. Patients must have recovered from effects of any recent major surgery
•7. Willing to use contraception if applicable
•8. Informed consent
•9. Life expectancy estimated to be more than 12 weeks; Target Gender: Male & Female ; Lower Age Limit 18 no age limit or unit specified

•1.Contraindications to FOLFOX chemotherapy: Peripheral neuropathy National Cancer Institute Common Toxicity Criteria (NCI CTC) >1, Liver failure, uncontrolled coronary heart disease, myocardial infarction within the previous 6 months.
•2. Unwilling or unable to comply with the study protocol
•3. Patients who are pregnant or lactating or contemplating pregnancy. Patients or their partners who become pregnant during the study will be referred to the appropriate experts.
•4. Undergone chemotherapy (other than adjuvant for CRC) or participating in another drug study.
•5. Previous cancer <5 years (other than colorectal, basal cell carcinoma, in-situ cervical cancer)
•6. Major surgery within 4 weeks of starting the study
•7. Co-existing active infection or serious concurrent medical condition
•8. Significant cardiovascular disease
•9. Bone metastases
•10. Known brain or leptomeningeal metastases
•11. Surgery or hospital admissions for symptomatic intra-abdominal adhesions
•12. Active endoscopically proven peptic ulcer disease or colitis

发起方

niversity of Leicester (UK)